WP
PSTX

Westmount Partners’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Westmount Partners’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-11,000
Closed -$106K – 250
2024
Q4 		$106K Hold
11,000
– – 0.03% 214
2024
Q3 		$31.5K Hold
11,000
– – 0.01% 224
2024
Q2 		$33.1K Hold
11,000
– – 0.01% 214
2024
Q1 		$35.1K Hold
11,000
– – 0.01% 208
2023
Q4 		$37K Hold
11,000
– – 0.02% 197
2023
Q3 		$26.2K Hold
11,000
– – 0.01% 190
2023
Q2 		$19.4K Hold
11,000
– – 0.01% 184
2023
Q1 		$33.9K Hold
11,000
– – 0.02% 179
2022
Q4 		$58.3K Buy
+11,000
New +$50.3K 0.03% 167

Other funds holding PSTX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Westmount Partners's PSTX Position: Q1 2025 in Review

Westmount Partners sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 11,000 shares — an estimated $106K sold.

Westmount Partners first reported a position in PSTX in Q4 2022 and held it in 9 quarters. The position peaked at $106K in Q4 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

  • Westmount Partners reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Westmount Partners sold 11,000 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $106K.
  • Westmount Partners first reported a position in Poseida Therapeutics, Inc. Common Stock in Q4 2022 and held it in 9 quarters.
  • Westmount Partners's Poseida Therapeutics, Inc. Common Stock position peaked at $106K in Q4 2024.
  • 1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Westmount Partners's 13F filing for Q1 2025, filed 1 May 2025.